Clinical studies to take care of unmet medical need post-transplantation A class of biotechnology medications known as monoclonal antibodies is now becoming tested in clinical studies to treat an unmet medical want post-transplantation, called delayed graft function It is not uncommon for kidney transplants to fail http://genericcialis-usa.com/studies-and-findings/ . Once transplanted, the kidney must connect back again with the blood circulation to start out working properly and become truly accepted by the body.
Cash and money equivalents at June 30, 2010 had been $63.5 million. This includes net proceeds of $29.9 million from a community offering of 2.2 million shares of common stock at a price of $14.30 per share that was completed on June 14, 2010.. Clinical Data first-quarter gross revenue increases 52 percent to $6.2 million Clinical Data, Inc. today announced operational and economic results for the first quarter ended June 30, 2010, noting essential accomplishments like the acceptance of the Company’s new drug application for vilazodone by the U.S. Food and Drug Administration and the successful completion of a general public providing. The additional funds we elevated from our general public offering will help drive aggressive industrial strategies for vilazodone and extends our current working assets beyond the PDUFA day.